LENZ Therapeutics, Inc.
LENZNASDAQHealthcare● Active
$6.94
+$0.22(+3.20%)
Market Cap$217442722
P/E Ratio—
52W High$50.4
52W Low$6.61
LENZ Therapeutics, Inc. (LENZ) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LENZ · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($82.13M) | ($49.77M) | ($69.97M) | ($101.05M) | ($70.76M) |
| Depreciation & Amort. | ($3.12M) | $0.06M | $0.01M | $8.35M | $0.73M |
| Stock-Based Comp. | $12.55M | $6.37M | $1.34M | $0.00M | $0.00M |
| Change in Working Capital | $3.25M | ($13.09M) | $9.41M | ($7.21M) | ($2.50M) |
| Net Cash from Operations | ($69.17M) | ($59.39M) | ($60.38M) | ($87.98M) | ($52.85M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.83M) | ($0.47M) | ($0.03M) | ($6.59M) | ($5.74M) |
| Purchases of Investments | ($280.80M) | ($241.91M) | ($52.09M) | ($405.52M) | $0.00M |
| Sales of Investments | $205.96M | $87.90M | $22.50M | $170.25M | $0.00M |
| Net Cash from Investing | ($75.67M) | ($154.48M) | ($29.62M) | ($241.86M) | ($5.74M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | ($0.08M) | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $149.75M | $199.00M | $80.70M | $0.60M | $417.47M |
| Free Cash Flow | |||||
| Free Cash Flow | ($70.00M) | ($59.86M) | ($60.41M) | ($94.57M) | ($58.59M) |
| FCF Margin %(computed) | -366.71% | — | — | -630.49% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more LENZ Therapeutics, Inc. data
About LENZ Therapeutics, Inc. (LENZ) Cash Flow Statement
LENZ Therapeutics, Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.07B) for 2025 — a FCF margin of -366.71%. Capital expenditure was ($0.00B).
Frequently asked questions
LENZ · 4 questionsLENZ Therapeutics, Inc. generated free cash flow of ($0.07B) for 2025, down 16.9% year-over-year.
LENZ free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10